Personalized CAR-T Immunotherapy Platform

Improved sensitivity for single gene mutation detection

IIn the era of the Cancer MoonShot 2020 Program the nation’s most comprehensive cancer collaborative initiative to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients DiaCarta and ProMab have joined hands to offer the next-generation Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy platform.


1500 existing hybridomas and antibody engineering


Custom lentiviral CAR construction (GMP)


High-throughput multiplex cytotoxicity assays


In vivo efficacy and toxicity validation


CAR-T cell manufacturing (GMP)


Biomarker discovery


Genomic profiling


Next-Generation Sequencing


CAR-T infusion treatment

Personalized CAR-T Immunotherapy Platform Service Overview

Genomic Profiling - Biomarker discovery and CAR-T profiling

  • Gene mutation analysis by XNA technology
  • Gene expression by QuantiMarker™ assays
  • OptiSeq™ next-generation sequencing
  • GLP and CLIA lab settings

Cytokines Assays - Bead-based multiplex protein tests run on Bio-Rad Bio-Plex®

  • Standard assays for cytokine detection in activated CAR-T cells (e.g. IL-2, IL-6, IFN-ϒ)
  • Customized assays for quantitating up to 50 cytokines
  • GLP and CLIA lab settings

CAR-T Services - Focus on generating CAR for murine-based pre-clinical studies or use as a clinical tool

  • Antibody discovery (hybridomas, mouse, rabbit and human library)
  • Customized lentiviral CAR construction
  • CAR-T cell manufacturing
  • Real-time cytotoxicity assay (RTCA)
  • Multiplex cytokine screening
  • Mouse in vivo efficacy and toxicology modeling
  • In vivo imaging by Xenogen/PerkinElmer IVIS system
  • GMP manufacturing of CD3/CD28 beads (coming soon)
  • GMP manufacturing of lentiviral CAR (coming soon)